SNAP‐Tag–Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light‐Accessible Melanotransferrin‐Expressing Melanoma and Triple‐Negative Breast Cancer
Open Access
- 6 May 2025
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 14 (9) , e70912
Abstract
Background: Melanoma and triple negative breast cancer (TNBC) represent the most aggressive skin and breast cancer subtypes and are associated with poor diagnostic and limited therapeutic options leading to poor prognosis. Melanotransferrin/p97 (MTf), initially identified as a tumor‐associated antigen (TAA) in melanoma, is overexpressed in various solid tumors, including TNBC. Beyond its high differential expression and dreadful tumorigenic impact, MTf is also associated with chemoresistance development, and its inhibition significantly hampers tumor progression, making MTf a promising target for effective targeted therapies. Near‐infrared photoimmunotherapy (NIR‐PIT) is an approach that combines the precision of antibodies directed against specific TAA with the phototoxic effects of a light‐sensitive photosensitizer (IR700), activated by near‐infrared (NIR) light irradiation. This study aimed to generate a novel photoimmunoconjugate to specifically destroy MTf‐positive melanoma and TNBC cells in vitro following NIR light irradiation. Methods: A single‐chain variable fragment (scFv) assembled from anti‐MTf antibody L49 was recombinantly fused with the SNAP‐tag protein (L49(scFv)‐SNAP), capable of irreversible and autocatalytic conjugation to any O(6)‐benzylguanine (BG) substrate in a 1:1 stoichiometry. Purified full‐length SNAP‐tag–based fusion protein (L49(scFv)‐SNAP‐tag) was either conjugated to a BG‐modified fluorescent imaging agent (Alexa 488) to specifically assess its selective binding to MTf‐expressing cell lines via confocal imaging and flow cytometry or to a BG‐modified light‐sensitive photosensitizer (IR700) to evaluate its phototoxic properties using an XTT cell viability assay. Results: The selective binding and internalization of L49(scFv)‐SNAP‐Alexa 488 towards MTf‐positive melanoma and TNBC cell lines were successfully demonstrated with MTF expression percentages ranging from 52.8 to 83.1. Once confirmed, dose‐dependent phototoxicity of L49(scFv)‐SNAP‐IR700 was achieved on illuminated MTf‐positive cell lines showing IC 50 values in the nanomolar range (2.20–5.24 nM). Conclusion: This study highlights the therapeutic potential of MTf as a promising target for the diagnosis as well as selective and efficient elimination of NIR‐light‐accessible melanoma and TNBC by NIR‐PIT.Keywords
Funding Information
- National Research Foundation (47904)
- University of Capetown
- Faculdade de Ciências da Saúde, Universidade de Macau
- Department of Science and Technology, Republic of South Africa
This publication has 84 references indexed in Scilit:
- Directed Evolution of O6-Alkylguanine-DNA Alkyltransferase for Efficient Labeling of Fusion Proteins with Small Molecules In VivoChemistry & Biology, 2003
- High transcytosis of melanotransferrin (P97) across the blood–brain barrierJournal of Neurochemistry, 2002
- Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endotheliumBrain Research, 1996
- Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein.Journal of Biological Chemistry, 1994
- Human melanotransferrin (p97) has only one functional iron‐binding siteFEBS Letters, 1992
- HOW DOES PHOTODYNAMIC THERAPY WORK?Photochemistry and Photobiology, 1992
- Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence.Proceedings of the National Academy of Sciences, 1986
- Human melanoma-associated antigen p97 is structurally and functionally related to transferrinNature, 1982
- Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.Proceedings of the National Academy of Sciences, 1981
- Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.Proceedings of the National Academy of Sciences, 1980